Depression News and Research

Latest Depression News and Research

$3.9 million Challenge grant for Thomas Jefferson researchers

Four researchers from Thomas Jefferson University have received $3.9 million in Challenge grant funds as part of the American Recovery and Reinvestment Act.

3 Nov 2009

Aethlon Medical begins collaborative biomarker program to study neurodegenerative disease

Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced today that it has initiated a collaborative biomarker discovery program with the Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine and the Sports Legacy Institute (SLI).

3 Nov 2009

NIH awards $4 million research grant to AllTranz

AllTranz, Inc., a specialty pharmaceutical company focused on developing drugs to treat a variety of neurologic and inflammatory disorders, today announced that it has been awarded a $4 million research grant from the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to advance the company’s transdermal tetrahydrocannabinol (THC) patch for the treatment of marijuana dependence and withdrawal.

3 Nov 2009

Not enough is being done to support patients suffering from tinnitus

As many as one in seven people will experience tinnitus, or ringing in their ears, at some time of their life, but not enough is being done to support patients who experience this distressing condition, according to an extensive research review in the November issue of the Journal of Clinical Nursing.

3 Nov 2009

Interim data from Schering-Plough's narlaprevir Phase IIa study

Schering-Plough Corporation reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.

3 Nov 2009

High prevalence of nocturnal teeth grinding in patients with OSA

There is a high prevalence of nocturnal teeth grinding, or bruxism, in patients with obstructive sleep apnea (OSA), particularly in Caucasians. New research presented at CHEST 2009, the 75th annual international scientific assembly of the American College of Chest Physicians (ACCP), found that nearly 1 in 4 patients with OSA suffers from nighttime teeth grinding; this seems to be especially more prevalent in men and in Caucasians compared with other ethnic groups.

3 Nov 2009

A look at faculty health

On average, research shows, the United States loses the equivalent of at least one entire medical school class each year to suicide1 - as many as 400 physicians. The book Faculty Health in Academic Medicine: Scientists, Physicians, and the Pressures of Success (Humana Press/Springer), by faculty at The University of Texas M. D. Anderson Cancer Center and other national medical experts, breaks new ground in a first-of-its-kind look at faculty health.

2 Nov 2009

Cyberonics to develop medical devices with cutting edge technology for persons suffering from epilepsy

Cyberonics, Inc. today announced another in a series of collaborations around seizure detection technology aimed at advancing its development of new and more efficacious medical devices for persons suffering from epilepsy.

2 Nov 2009

Deep brain stimulation can help patients with severe forms of depression

In deep brain stimulation, doctors specifically target the impaired function of certain areas of the brain with an electric brain pacemaker. For the purpose of this study, they implanted electrodes in what is known as the nucleus accumbens. That is an important part of the 'reward system' which ensures that we remember good experiences and puts us in a state of pleasant anticipation.

2 Nov 2009

Virtual world solution to address the unique needs of military amputees

Virtual worlds can provide military amputees with an opportunity to enhance their overall quality of life, expedite their reintegration into society, and improve their physical and mental wellness.

2 Nov 2009

Gilead Sciences to present Viread Phase III clinical trial data

Gilead Sciences, Inc. today announced the presentation of three-year (144-week) open label data from two pivotal Phase III clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread® (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection.

2 Nov 2009

Study examines trajectories in sleep disturbances before and after retirement over an extended time window

A study in the Nov.1 issue of the journal Sleep shows that retirement is followed by a sharp decrease in the prevalence of sleep disturbances. Findings suggest that this general improvement in sleep is likely to result from the removal of work-related demands and stress rather than from actual health benefits of retirement.

2 Nov 2009

Shire to present key data on ADHD treatments at national psychiatric meeting

Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV- (guanfacine) Extended Release Tablets, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, and Daytrana- (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.

31 Oct 2009

Molecular imaging pinpoints inflammation in the brains of schizophrenics and migraine sufferers

Inflammatory response of brain cells-as indicated by a molecular imaging technique-could tell researchers more about why certain neurologic disorders, such as migraine headaches and psychosis in schizophrenic patients, occur and provide insight into how to best treat them, according to two studies published in the November issue of the Journal of Nuclear Medicine.

31 Oct 2009

Shire announces Phase IIIb study results of Daytrana

Shire plc, the global specialty biopharmaceutical company, today announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of Daytrana® (methylphenidate transdermal system) in adolescents aged 13 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).

31 Oct 2009

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Schering-Plough Corp. announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.

31 Oct 2009

Stress-evoked changes can precipitate low mood and re-ignite drug-seeking behaviors

Stress-evoked changes in circuits that regulate serotonin in certain parts of the brain can precipitate a low mood and a relapse in cocaine-seeking, based on mouse studies published online this week in the Proceedings of the National Academy of Sciences.

31 Oct 2009

FDA approves Covidien's Abbreviated New Drug Application for CII

Covidien, a leading global provider of healthcare products, today announced that its subsidiary, Mallinckrodt Inc., has received U.S. Food and Drug Administration (FDA) approval of its Abbreviated New Drug Application (ANDA) for Oral Transmucosal Fentanyl Citrate (CII).

31 Oct 2009

Individualized MicroNutrient Testing for patients

In response to the current trend toward personalized medicine, the Beaumont Weight Control Center, affiliated with Beaumont Hospitals, a major Detroit-area health system, now offers individualized MicroNutrient Testing for patients.

31 Oct 2009

60 Plus Association calls upon Sen. Lieberman not to support any bill which cuts Medicare

Today, the 60 Plus Association released a new TV ad targeting Senator Joe Lieberman (D-Conn.). The ad features members of our Greatest Generation begging Sen. Lieberman not to cut Medicare to pay for health care reform. The :30 second TV ad will run in conjunction with a :60 second ad that began airing on Wednesday.

30 Oct 2009